TABLE I

[human papillomavirus (HPV) DNA detection, HPV16 typing, and p16ink4a methylation - Nested-MSP], including the sequence of each primer, Description of used primers during polymerase chain reaction (PCR). The table describes sets of primers in each PCR assay nucleotide position at the genome of reference, amplicon size and literature which designed was based


Assav			Primers (5'-3')	Nt position	Amplicon size (bn)	Reference
Constant				Jan	(Ac)	
HPV DNA detection	MY11	forward:	GCMCAGGGWCATAAYAATGG	*	64	Bauer et al.(33)
	MX09	reverse:	CGTCCMARRGGAWACTGATC	*	420	
HPV16 typing	$E6 \text{ HPV} 16_{Pl}$	forward:	CCCAGAAAGTTACCACAG	128 - 262	135	Moljin et al.(34) Nucleotide position based on
	$E6 \text{ HPV} 16_{P2}$	reverse:	TACTATGCATAAATCCCG	707 - 071	001	HPV16REF (GenBank: K02718.1)
EI/E2 gene integrity	<u>т</u>	forward:	CCATGGCTGATCCTGCAG	863 - 1719	357	Vernon et al.(18)
	3	reverse:	TCTCCTTTTTGCAGCTCT			
	417	forward:	GACAGCGGGTATGGCAAT	1754 1662	710	
	EID	reverse:	CATTCCCCATGAACATGC	1234 - 1003	410	
	710	forward:	AATAAATCAACGTGTTGCGATTGG	1540 2004	537	
	EIC	reverse:	GTTTATAATGTCTACACATTGTTG	1340 - 2004	/66	
		forward:	GGATTGTGCAACAATGTG	FC3C CEOC	727	
	EIG	reverse:	TGGAGGCATTTTAGTTG	777 - 777	430	
	ļ.	forward:	CAACTAAAATGCCCTCCA	3100 0030	717	
	Ele	reverse:	CGCATGTTTTCCAATAG	2329 - 2043	21/	
	A CT	forward:	CGAGGACAAGGAAAACGA	2728 2180	757	
	H77	reverse:	CTTGACCCTCTACCACAG	21.30 = 3103	70+	
	F2B	forward:	GGTTTATATTATGTTCATGAAGG	3220 3500	380	
	777	reverse:	TATGGGTGTAGTGTTACTATTACA	0000 - 0770	200	
	Ç	forward:	GTAATAGTAACACTACACCCATA	1506 3050	050	
	EZC	reverse:	GGATGCAGTATCAAGATTTG	5005 - 0606	007	
Nested-MSP	p16-outer1	forward:	GAAGAAAGAGGAGGGTTGG	01074658 01074030	273	Palmisano et al. (35). Nucleotide position based on Chr9
	p16-outer2	reverse:	CTACAAACCCTCTACCCACC	06641617 - 06041617	C 1 7	GRCh37.p13
	p16-M1	forward:	TTATTAGAGGGTGGGGGCGGATCGC	30017017 73717017	150	
C	p16-M2	reverse:	GACCCCGAACCGCGACCGTAA	0064/617 - /6/4/617	001	
UPP	p16-U1	forward:	TTATTAGAGGGGGGGGGGGATTGT	20077010 332772010	151	
OI EA	p16-U2	reverse:	CAACCCCAAACCACAACCATAA	21974/30 - 21974900	101	

M = A+C; R = A+G; W = A+T; Y = C+T; Nested-MSP = nested methylated specific PCR; TA = annealing temperature; Nt position = nucleotide position; \*: variable depending HPV genotype.

TABLE II Compilation of all molecular and clinical information. The table depicts all information regarding samples herein studied, including cytology [low-grade squamous intraepithelial cells (LSIL), high grade squamous intraepithelial cells (HSIL), and cervical cancer (CC)], age, E1/E2 integrity and p16<sup>ink4a</sup> promoter methylation status

	cervical cancer (ce)j, a	ge, E1/E2 integrity and p10	promoter methylation s	tatus
Sample id	cytology	age	E1/E2_integrity	p16 Methylation
Sample 01	LSIL	45	Disrupted in E1/E2	unmethylated
Sample 02	LSIL	51	Disrupted in E1/E2	unmethylated
Sample 03	LSIL	32	Disrupted in E1/E2	unmethylated
Sample 04	LSIL	52	Disrupted in E1/E2	unmethylated
Sample 05	HSIL	47	Disrupted in E1/E2	methylated
Sample 06	LSIL	38	Disrupted in E1/E2	unmethylated
Sample 07	LSIL	23	Disrupted in E1/E2	unmethylated
Sample 08	HSIL	48	Disrupted in E2	unmethylated
Sample 09	LSIL	26	Disrupted in E1/E2	unmethylated
Sample 10	LSIL	50	Disrupted in E1/E2	unmethylated
Sample 11	LSIL	52	Disrupted in E1/E2	methylated
Sample 12	LSIL	39	Disrupted in E1/E2	unmethylated
Sample 13	HSIL	25	Disrupted in E1/E2	methylated
Sample 14	HSIL	25	Disrupted in E1/E2	unmethylated
Sample 15	HSIL	26	Disrupted in E1/E2	methylated
Sample 16	HSIL	25	Disrupted in E1/E2	methylated
Sample 17	HSIL	37	Disrupted in E1/E2	unmethylated
Sample 18	LSIL	24	Disrupted in E1/E2	methylated
Sample 19	HSIL	34	Disrupted in E1/E2	unmethylated
Sample 20	HSIL	33	Disrupted in E1/E2	unmethylated
Sample 21	HSIL	45	Intact	unmethylated
Sample 22	HSIL	28	Disrupted in E1/E2	unmethylated
Sample 23	HSIL	34	Intact	methylated
Sample 24	LSIL	48	Intact	methylated
Sample 25	LSIL	36	Disrupted in E1/E2	unmethylated
Sample 26	HSIL	43	Disrupted in E1	methylated
Sample 27	HSIL	25	Intact	unmethylated
Sample 28	HSIL	76	Intact	methylated
Sample 29	HSIL	64	Disrupted in E1/E2	unmethylated
Sample 30	HSIL	47	Disrupted in E1/E2	methylated
Sample 31	CC - SCC	56	Disrupted in E1/E2	methylated
Sample 32	CC - SCC	37	Intact	methylated
Sample 33	HSIL	31	Intact	unmethylated
Sample 34	CC - SCC	44	Disrupted in E1/E2	methylated
Sample 35	HSIL	44	Disrupted in E1/E2	unmethylated
Sample 36	LSIL	43	Intact	unmethylated
Sample 37	CC - SCC	62	Disrupted in E2	unmethylated
Sample 38	HSIL	30	Disrupted in E1/E2	methylated
Sample 39	LSIL	25	Intact	methylated
Sample 40	CC - SCC	36	Disrupted in E1/E2	methylated
Sample 41	HSIL	37	Disrupted in E1/E2	methylated
Sample 42	HSIL	58	Disrupted in E1/E2	methylated
Sample 43	CC - SCC	43	Disrupted in E1/E2	methylated
Sample 44	CC - SCC	25	Disrupted in E1/E2	methylated
Sample 45	LSIL	30	Intact	unmethylated
Sample 46	LSIL	18	Disrupted in E1/E2	methylated
Sample 47	HSIL	41	Intact	methylated
Sample 48	CC - SCC	48	Disrupted in E1/E2	methylated
Sample 49	HSIL	28	Intact	methylated

Sample id	cytology	age	E1/E2_integrity	p16 Methylation
Sample 50	HSIL	38	Disrupted in E1	unmethylated
Sample 51	CC - SCC	58	Disrupted in E1/E2	methylated
Sample 52	LSIL	26	Intact	unmethylated
Sample 53	CC - SCC	30	Disrupted in E1/E2	methylated
Sample 54	HSIL	52	Intact	methylated
Sample 55	LSIL	38	Disrupted in E1/E2	methylated
Sample 56	LSIL	23	Disrupted in E1/E2	methylated
Sample 57	LSIL	30	Disrupted in E1/E2	methylated
Sample 58	CC - SCC	44	Intact	unmethylated
Sample 59	HSIL	36	Intact	methylated
Sample 60	HSIL	51	Disrupted in E1/E2	methylated
Sample 61	HSIL	25	Intact	unmethylated
Sample 62	LSIL	27	Disrupted in E2	methylated
Sample 63	HSIL	68	Disrupted in E1/E2	methylated
Sample 64	HSIL	38	Intact	unmethylated
Sample 65	LSIL	44	Disrupted in E1/E2	methylated
Sample 66	CC - SCC	34	Disrupted in E1/E2	unmethylated
Sample 67	LSIL	21	Disrupted in E1/E2	unmethylated
Sample 68	CC - SCC	44	Intact	methylated
Sample 69	LSIL	28	Disrupted in E1/E2	unmethylated
Sample 70	LSIL	28	Intact	methylated
Sample 71	HSIL	34	Intact	methylated
Sample 72	LSIL	51	Disrupted in E1	methylated
Sample 73	CC - Adeno	59	Disrupted in E1/E2	methylated
Sample 74	HSIL	31	Intact	methylated
Sample 75	HSIL	51	Intact	methylated
Sample 76	HSIL	41	Intact	methylated
Sample 77	CC - SCC	34	Disrupted in E1/E2	methylated
Sample 78	HSIL	29	Disrupted in E1/E2	methylated
Sample 79	HSIL	29	Disrupted in E1/E2	unmethylated
Sample 80	LSIL	25	Disrupted in E1/E2	methylated
Sample 81	HSIL	25	Disrupted in E1/E2	methylated
Sample 82	LSIL	42	Disrupted in E1/E2	methylated
Sample 83	HSIL	50	Intact	unmethylated
Sample 84	HSIL	50	Disrupted in E1/E2	unmethylated
Sample 85	HSIL	25	Disrupted in E1/E2	unmethylated
Sample 86	CC - SCC	48	Disrupted in E1/E2	methylated
Sample 87	CC - SCC	51	Disrupted in E1/E2	methylated



Products of cervical smear samples in the Nested-MSP. The gel (Agarose1.5%/TAE 1x) shows one unmethylated sample A (band positive on p16U and negative on p16M), and two methylated samples B/C positive for both primer pairs. Methylation of  $p16^{ink4a}$  gene was considered to be present if amplification was obtained by both, M and U primers, or only M positive, after sodium bisulfite modification. The molecular weight standard used was ladder 100bp (Invitrogen).